These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | McGuff Pharmaceuticals, Inc. dba McGuff Outsourcing Solutions |
| Location | Santa Ana, California |
| Type | 503B outsourcing facility |
| Registered since | January 11, 2023 |
| Latest registration | December 2, 2025 |
| Last FDA inspection | Not yet inspected |
| Inspection dates | — |
| Form 483 | Not issued |
| FDA action after the inspection | None listed |
| Compounds sterile drugs from bulk | Yes |
| FDA warning letters on GLP-1 drugs | 0 |
Has this facility recalled any drugs?
FDA’s enforcement reports list 4 recalled products from this facility, from January 10, 2019 to December 8, 2022: 4 in Class II. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2022-12-08 | II | Thiamine Hydrochloride 200 mg/2mL (100mg/mL) | Presence of Particulate Matter: Presence of foreign substances were reported in vials at the pharmacy. |
| 2022-12-08 | II | Thiamine Hydrochloride 3000 mg/30 mL (100mg/mL) | Presence of Particulate Matter: Presence of foreign substances were reported in vials at the pharmacy. |
| 2019-02-14 | II | Dimercaptopropanesulfonate Sodium (DMPS) | Presence of Particulate Matter: Particulates observed in vials release for dispensing. |
| 2019-01-10 | II | Lipoic Acid Injection (aka Alpha Lipoic Acid or Thioctic Acid) | Presence of Particulate Matter: filmy/cloudy particulate observed in vial. |
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
8 of the 100 facilities on FDA’s list are in California. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Registered outsourcing facilities: inspection status of McGuff Pharmaceuticals, Inc. dba McGuff Outsourcing Solutions. fda.gov
- FDA. Drug recall enforcement reports for McGuff Pharmaceuticals, Inc. dba McGuff Outsourcing Solutions, read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider